Zusammenfassung
Unter dem Überbegriff Osteopathien werden verschiedene Knochenerkrankungen zusammengefasst. Man differenziert die metabolischen Osteopathien von zirkulatorischen Störungen (Osteonekrosen) und toxischen, infektiösen sowie neoplastischen Osteopathien. Zu den metabolischen Osteopathien wird eine Reihe von Krankheiten gezählt, deren Ursachen sehr unterschiedlich sind, z. B. Hyper- und Hypoparathyreoidismus. Im nachfolgenden Kapitel wird vor allem auf Osteoporose und Osteomalazie eingegangen, der M. Paget ist in Kap. 7.2 ausführlich dargestellt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bilezikian JP, Raisz LG, Rhodan GA (1996) Principles of bone biology. Academic Press, San Diego London Boston New York Sydney Tokyo Toronto
Consensus Development Statement (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 7: 1–6
Dambacher MA, Neff M (2001) Erworbene Skelettsystemerkrankungen. In: Wirth CJ (Hrsg) Praxis der Orthopädie. Thieme, Stuttgart New York, S 371–414
Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282: 637–645
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures. BMJ 12: 1254–1259
McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333–340
Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441
NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785–795
Seibel MJ, Stracke H (1997) Metabolische Osteopathien. Schattauer, Stuttgart
Bone HG, Kleerekoper M (1992) Clinical review 39: Paget’s disease of bone. J Clin Endocrinol Metab 75: 1179–1182
Drake WM, Kendler DL, Brown JB (2001) Consensus statement on the modern therapy of Paget’s disease of bone from a western osteoporosis alliance symposium. Clin Ther 23: 620–626
Feldkamp J, Scherbaum WA (2001) Risedronsäure, neues Bisphosphonat zur Therapie und Prophylaxe der Osteoporose. Arzneimitteltherapie 19: 38–44
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961–2978
Siris ES (1999) Goals of treatment for Paget’s disease of bone. J Bone Miner Res 14 (Suppl 2): 49–52
Baitner AC, Maurer SG, Gruen MB, Di Cesare PE (2000) The genetic basis of the osteochondrodysplasias. J Pediatr Orthop 20: 594–605
Candelierer G, Glorieux FH, Prud’Homme J, St.-Arnaud R (1995) Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332: 1546–1551
Tilstra DJ, Byers PH (1994) Molecular basis of hereditary dis- orders of connective tissue. Annu Rev Med 45: 149–163
Vanhoenacker FM, De Beuckeleer LH, Van Hul W, Balemans W, Tan GJ, Hill SC, De Schepper AM (2000) Sclerosing bone dysplasias: genetic and radiolclinical features. Eur Radiol 10: 1423–1433
Brandt KD, Doherty M, Lohmander LS (1998) Osteoarthritis. Oxford University Press, Oxford
Coventry MB (1993) Proximal tibial osteotomy. J Bone Jt Surg 75-A: 196–201
Fuchs S (1999) Bedeutung der Tibiakopfumstellungsosteotomie im Zeitalter von Endoprothesen. Z Orthop 37: 153–258
Hassenpflug J, von Haugwitz A, Hahne HJ (1998) Long term results of tibial head osteotomy. Z Orthop 36: 154–161
Tönnis D, Heinecke A (1999) Acetabular and femoral anteversion: relationship with osteoarthritis of the hip. J Bone Joint Surg Am 81: 1747–1770
Hochberg MC (2001) What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist’s perspective. Clin Exp Rheumatol 19 (Suppl 25): S15 - S22
Jackson LM, Hawkey CJ (2000) COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 59: 1207–1216
Cheung HS (2000) Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol 12: 223–227
Fam AG (2000) What is new about crystals other than monosodium urate? Curr Opin Rheumatol 12: 228–234
Dihlmann W (1987) Gelenke - Wirbelverbindungen. Klinische Radiologie einschließlich Computertomographie - Diagnose, Differentialdiagnose, 3. Aufl. Thieme, Stuttgart New York
Donatto KC (1998) Orthopedic management of septic arthritis. Rheum Dis Clin North Am 24: 275–286
Goldenberg DL (1998) Septic Arthritis. Lancet 351: 197–202
Groß DM, Forsthuber T, Tary-Lehmann M et al. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme-arthritis. Science 281: 703–706
Gupta MN, Sturrock RD, Field M (2001) A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology 40: 24–30
Hogan CJ, Fang GD, Scheid WM, Linden J, Diduch DR (2001) Inhibiting the inflammatory response in joint sepsis. Arthroscopy 17: 311–315
Jalava J, Skurnik M, Toivanen A, Toivanen P, Eerola E (2001) Bacterial PCR in the diagnosis of joint infection. Ann Rheum Dis 60: 287–289
Krijnen P, Kaandorp CJ, Steyerberg EW, van Schaardenburg D, Moens HJ, Habbema JD (2001) Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis. Ann Rheum Dis 60: 359–366
Stutz G, Kuster MS, Kleinstuck F, Gachter A (2000) Arthroscopic management of septic arthritis: stages of infection and results. Knee Surg Sports Traumatol Arthrosc 8: 270–274
Thaler SJ, Maguire JH (1998) Infectious arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ et al. (eds) Harrison’s principles of internal medicine, 14. edn. McGraw-Hill, New York-Toronto
van der Heijden IM, Wilbrink B, Schouls LM, van Embden JD, Breedveld FC, Tak PP (1999) Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis. Rheumatology 38: 547–553
Verdrengh M, Tarkowski A (2000) Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis. Arthritis Rheum 43: 2276–2282
Wormser GP, Nadelmann RB, Dattwyler RJ et al. (2000) Practice guidelines for the treatment of lyme disease. Clin Infect Dis 31 (Suppl 1): 51–514
Zeidler H, Zacher J, Hiepe F (Hrsg) (2001) Interdisziplinäre klinische Rheumatologie: Innere Medizin - Orthopädie - Immunologie. Springer, Berlin Heidelberg New York Tokyo
Breedfeld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59: 841–849
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflam- mation in rheumatoid arthritis. N Engl J Med 344: 907–916
Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, Van De Putte LB (2000) Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43: 4–13
Firestein GS (2001) Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology. WB Saunders, Philadelphia
Furst DE et al. (2002) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 61 (Suppl II): ii2-ii7
Harris ED (2001) Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley’s textbook of rheumatology. WB Saunders, Philadelphia
Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341–1359
O’Dell JR, Scott DL (1999) Rheumatoid arthritis: new developments in the use of existing therapies. Rheumatology 38 (Suppl 2): 24–26
Plant MJ, Jones PW, Saldatvala J, Oilier WE, Dawes PT (1998) Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 25: 417–426
Ryan L, Brooks P (1999) Disease modifying antirheumatic drugs. Curr Opin Rheumatol 11: 161–166
Spencer-Green G (2000) Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 59 (Suppl 1): i46 - i49
Taylor PC (2001) Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 13: 164–169
Verhoeven AC, Boers M, Tugwell P (1998) Combination therapy in rheumatoid arthritis: An updated systematic review. Br J Rheumatol 37: 1102–1109
Bywaters EGL (1971) Still’s disease in the adult. Ann Rheum Dis 31: 121–133
Cush JJ, Medsger TA Jr, Christy WC et al. (1987) Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum 30: 186–194
Delpech M, Grateau G (2001) Genetically determined recurrent fevers. Curr Opin Immunol 13: 539–542
Fautrel B, Borget C, Rozenberg S et al. (1999) Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol 26: 373–378
Fautrel B, Le Moel G, Saint-Marcoux B et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 28: 322–329
Khraishi M, Fam AG (1991) Treatment of fulminant adult Still’s disease with intravenous pulse methylprednisolone therapy. J Rheumatol 18: 1088–1090
Pouchot J, Sampalis JS, Beaudet F et al. (1991) Adult Still’s disease: Manifestations, disease course, and outcome in 62 patients. Medicine 70: 118–136
Yamaguchi M, Ohta A, Tsunematsu T et al. (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19: 424–430
Adam D, Scholz H, Helmerking M (2000) Short-course antibiotic treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 182: 509–516
Albert DA, Harel L, Karrison T (1995) The treatment of rheuma- tic carditis: a review and meta-analysis. Medicine 74: 1–12
Bisno AL (2000) Nonsuppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edn. Churchill Livingstone, Philadelphia, p 2117–2128
Del Mar CB, Glasziou PP, Spinks AB (1/2002) Antibiotics for sore throat (Cochrane Review). In: The Cochrane Library. Oxford: Update Software
Gibofsky A, Kerwar S, Zabriskie JB (1998) Rheumatic fever. The relationship between host, microbe, and genetics. Rheum Dis Clin N Am 24: 237–259
Lue HC, Wu MH, Wang JK, Wu FF, Wu YN (1994) Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 125: 812–816
Oen K (2000) Comparative epidemiology of the rheumatic diseases in children. Curr Opin Rheumatol 12: 410–414
Olivier C (2000) Rheumatic fever–is it still a problem? J Antimicrob Chemother 45: 13–21
Special writing group of the committee on rheumatic fever, endocarditis and Kawasaki disease of the council on cardiovascular disease in the young of the American Heart Association (1992) Guidelines for the diagnosis of rheumatic fever. Jones criteria,1992 update. JAMA 2069–2073
Brandt J, Haibel H, Comely D et al. (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43: 1346–1352
Calin A, Porta J, Fries JF, Schurmann DJ (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237: 2613–2614
Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34: 1218–1227
Goie HS, Steven MM, van der Linden S, Cats A (1985) Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24: 242–249
Mau W, Zeidler H, Mau R et al. (1990) Evaluation of early diagnostic criteria for ankylosing spondylitis in a 10 year follow-up. Z Rheumatol 49: 82–87
Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A (2001) Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 13: 280–284
Toivanen A (2001) Bacteria-triggered reactive arthritis: implications for antibacterial treatment. Drugs 61: 343–351
Toivanen A, Toivanen P (2000) Reactive arthritis. Curr Opin Rheumatol 12: 300–305
van der Linden S, van der Heijde D (2000) Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol 12: 263–268
Girolomoni G, Abeni D (2001) Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 137 (6): 784–785
Helliwell PS, Wright V (1994) Psoriatic arthritis. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St. Louis
Jones G, Crotty M, Brooks P (2000) Interventions for psoriatic arthritis. Cochrane Database Syst Rev 3: CD000212
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55–78
Mrowietz U (2001) Advances in systemic therapy for psoriasis. Clin Exp Dermatol 26: 362–367
Patel S, Veale D, Fitzgerald O, McHugh NJ (2001) Psoriatic arthri- tis-emerging concepts. Rheumatology (Oxford) 40: 243–246
Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13 (5): 589–593
Veys EM, Mielants H (1994) Enteropathic arthropathies. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St. Louis
Zachariae H (1999) Renal toxicity of long-term ciclosporin. Scand J Rheumatol 28: 65–68
Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Le syndrome hyperosotse osteite (SAPHO). Resultats d’une enquete nationale: 85 observations. Rev Rhum Mal Osteoartic 187–196
Edlund E, Johnsson U, Lidgren L, Petterson H, Sturfelt G, Svensson B et al. (1988) Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis 47: 809–815
Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoiffman O et al. (1999) SAPHO syndrome: a longterm follow-up study of 120 cases. Semin Arthritis Rheum 29: 251–256
Kahn MF, Bouvier MB, Palazzo E, Tebib J, Colson F (1991) Sternoclavicular pustulotitc osteitis (SAPHO). 20 year interval between skin and bon lesions. J Rheumatol 18: 1104–1108
Kahn MF, Chamot AM (1992) SAPHO syndrome. Rheum Dis Clin N Am 18: 225–246
Kahn MF, Khan MA (1994) The SAPHO syndrome. Ballières Clin Rheumatol 8: 333–362
Sonozaki H, Mitsui H, Miyanaga Y, Okitsu K, Igarashi M, Hayashi Yet al. (1981) Clinical features of 53 cases with pustlotic arthroosteitis. Ann Rheum Dis 40: 547–553
Van Doornum S, Barraclough D, McColl G, Wicks I (2000) SAPHO: Rare or just not recognized? Semin Arthritis Rheum 30: 70–77
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schröder, J.O. et al. (2003). Erkrankungen von Knochen, Muskeln und Gelenken. In: Schölmerich, J., et al. Medizinische Therapie in Klinik und Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-12451-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-662-12451-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-12452-9
Online ISBN: 978-3-662-12451-2
eBook Packages: Springer Book Archive